Olig2 Inhibitor Compounds for Glioblastoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current brain tumor therapeutic agents extend median survival by only six months but cause significant systemic toxicity, leading to long-term morbidity, and are unable to cure brain tumors, which have a median survival of fifteen months.
Innovation Solution
Development of compounds of Formula (I), (II), (III), and (IV) that inhibit Olig2 activity, specifically designed to target and modulate the neural and glioblastoma stem cell transcriptional repressor OLIG2, offering a therapeutic approach with potentially lower toxicity and improved efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If current brain tumor therapeutic agents are used, then median survival is extended by six months, but significant systemic toxicity occurs leading to long-term morbidity
Solution Approach 1:
The patent changes the chemical parameters of the therapeutic agents by developing novel compounds with specific molecular structures (Formula I, II, III, IV) that target Olig2. This structural parameter change aims to achieve selective inhibition of Olig2 in brain tumor cells while reducing non-specific systemic toxicity, thereby extending survival without the severe side effects of conventional agents
Solution Approach 2:
The patent introduces Olig2 as a specific intermediary target - a transcription factor highly expressed in brain tumor stem cells. By designing compounds that specifically bind and inhibit Olig2, the therapy acts through this intermediary to selectively affect tumor cells while sparing normal tissues, thus reducing systemic toxicity while maintaining survival benefit
2Duration of action of moving object
If current brain tumor therapeutic agents are used, then median survival reaches fifteen months, but the tumors remain essentially incurable
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism driving brain tumor persistence - the Olig2 transcription factor in tumor stem cells. By isolating and inhibiting this specific target rather than using non-specific cytotoxic agents, the therapy aims to achieve complete tumor eradication (cure) rather than merely extending survival, while maintaining the median survival of fifteen months
3Reliability
If compounds of Formula (I), (II), (III), or (IV) are used to inhibit Olig2 activity, then therapeutic efficacy is improved with reduced toxicity, but compound structure complexity increases
Solution Approach 1:
The patent segments the complex therapeutic challenge into specific molecular components by designing compounds with distinct structural modules (Formula I, II, III, IV). Each formula represents a segmented approach with specific substituents (R1-R22 groups) that can be independently optimized. This segmentation allows systematic development of compounds with improved therapeutic margins while managing structural complexity through modular design
Data Source
AI summary
Described herein are compounds and pharmaceutical compositions of phenyl-pyrimidinyl-urea derivatives, which inhibit the activity of Olig2. An example of a phenyl-pyrimidinyl-urea derivative has the following structure:Also described herein are methods using the Olig2 inhibitors for treating cancer and other diseases. The Olig2 inhibitors may be used to treat glioblastoma.